{"url":"https://lda.senate.gov/api/v1/filings/5dc049c3-e283-4503-a950-664a2cbdffbe/","filing_uuid":"5dc049c3-e283-4503-a950-664a2cbdffbe","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2015,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/5dc049c3-e283-4503-a950-664a2cbdffbe/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Robert Armitage","dt_posted":"2016-01-04T20:57:50.267000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"320 Seaview Court","registrant_address_2":"Apt. 1811","registrant_different_address":false,"registrant_city":"Marco Island","registrant_state":"FL","registrant_zip":"34145","registrant":{"id":401103512,"url":"https://lda.senate.gov/api/v1/registrants/401103512/","house_registrant_id":null,"name":"ROBERT ARMITAGE","description":"consultant","address_1":"320 Seaview Court","address_2":"Apt. 1811","address_3":null,"address_4":null,"city":"Marco Island","state":"FL","state_display":"Florida","zip":"34145-2950","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ROBERT ARMITAGE","contact_telephone":"+1 703-801-6334","dt_updated":"2022-04-06T16:06:43.610267-04:00"},"client":{"id":199236,"url":"https://lda.senate.gov/api/v1/clients/199236/","client_id":12,"name":"ELI LILLY AND COMPANY","general_description":"research/manufacturing","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2015-02-18"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.),Dormant Therapies Act (S. 3004, 113th Cong.), the Innovation Act (H.R. 9, 114th Cong.) and the PATENT Act (S. 1137, 114th Cong.).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62862,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"ALLEN","last_name":"ARMITAGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Biopharmaceutical-related IP protection issues, including those associated with the MODDERN Cures Act (H.R. 3116, 113th Cong.) and Dormant Therapies Act (S. 3004, 113th Cong.).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62862,"prefix":null,"prefix_display":null,"first_name":"ROBERT","nickname":null,"middle_name":"ALLEN","last_name":"ARMITAGE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}